[1] Matthay MA, Zemans RL. The acute respiratory distress syndrome: pathogenesis and treatment[J]. Annu Rev Pathol, 2011, 6: 147-163.
[2] Cross LJ, Matthay MA. Biomarkers in acute lung injury: insights into the pathogenesis of acute lung injury[J]. Crit Care Clin, 2011, 27(2): 355-377.
[3] Hu X, Qian S, Xu F, et al. Incidence, management and mortality of acute hypoxemic respiratory failure and acute respiratory distress syndrome from a prospective study of Chinese Paediatric Intensive Care Network[J]. Acta Paediatr, 2010, 99(5): 715-721.
[4] Mcclintock D, Zhuo H, Wickersham N, et al. Biomarkers of inflammation, coagulation and fibrinolysis predict mortality in acute lung injury[J]. Crit Care, 2008, 12(2): R41.
[5] Uchida T, Shirasawa M, Ware LB. Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury[J]. Am J Respir Crit Care Med, 2006, 173(9): 1008-1015.
[6] Fineschi S, De Cunto G, Facchinetti F, et al. Receptor for advanced glycation end products contributes to postnatal pulmonary development and adult lung maintenance program in mice[J]. Am J Respir Cell Mol Biol, 2013, 48(2):164-171.
[7] Zhang H, Tasaka S, Shiraishi Y, et al. Role of soluble receptor for advanced glycation end products on endotoxin-induced lung injury[J].Am J Respir Crit Care Med, 2008, 178(4): 356-362.
[8] Christaki E, Opal SM, Keith JJ, et al. A monoclonal antibody against RAGE alters gene expression and is protective in experimental models of sepsis and pneumococcal pneumonia[J]. Shock, 2011, 35(5): 492-498.
[9] Silveyra P, Floros J. Genetic variant associations of human SP-A and SP-D with acute and chronic lung injury[J]. Front Biosci, 2012, 17: 407-429.
[10] Mosbah AA, Abdellatif NA, Sorour EI, et al. Serum SP-D levels as a biomarker of lung injury in children suffering of bronchopneumonia[J]. J Egypt Soc Parasitol, 2012, 42(1): 25-32.
[11] Clark HW. Untapped therapeutic potential of surfactant proteins: is there a case for recombinant SP-D supplementation in neonatal lung disease?[J]. Neonatology, 2010, 97(4): 380-387.
[12] Kondo T, Hattori N, Ishikawa N, et al. KL-6 concentration in pulmonary epithelial lining fluid is a useful prognostic indicator in patients with acute respiratory distress syndrome[J]. Respir Res, 2011, 12: 32.
[13] Determann RM, Royakkers AA, Haitsma JJ, et al. Plasma levels of surfactant protein D and KL-6 for evaluation of lung injury in critically ill mechanically ventilated patients[J]. BMC Pulm Med, 2010, 10: 6.
[14] Abdel-Latif ME, Osborn DA. Intratracheal Clara cell secretory protein (CCSP) administration in preterm infants with or at risk of respiratory distress syndrome[J]. Cochrane Database Syst Rev, 2011(5): D8308.
[15] Kropski JA, Fremont RD, Calfee CS. Clara cell protein (CC16), a marker of lung epithelial injury, is decreased in plasma and pulmonary edema fluid from patients with acute lung injury[J]. Chest, 2009, 135(6): 1440-1447.
[16] Determann RM, Millo JL, Waddy S, et al. Plasma CC16 levels are associated with development of ALI/ARDS in patients with ventilator-associated pneumonia: a retrospective observational study[J]. BMC Pulm Med, 2009, 9:49.
[17] Menoret A, Kumar S, Vella AT. Cytochrome b5 and cytokeratin 17 are biomarkers in bronchoalveolar fluid signifying onset of acute lung injury[J]. PLoS One, 2012, 7(7): e40184.
[18] Katayama M, Ishizaka A, Sakamoto M, et al. Laminin gamma2 fragments are increased in the circulation of patients with early phase acute lung injury[J]. Intensive Care Med, 2010, 36(3): 479-486.
[19] Urich D, Eisenberg JL, Hamill KJ, et al. Lung-specific loss of the laminin alpha3 subunit confers resistance to mechanical injury[J]. J Cell Sci, 2011, 124(Pt 17): 2927-2937.
[20] Mcclintock DE, Starcher B, Eisner MD, et al. Higher urine desmosine levels are associated with mortality in patients with acute lung injury[J]. Am J Physiol Lung Cell Mol Physiol, 2006, 291(4): L566-L571.
[21] Goodman RB, Pugin J, Lee JS, et al. Cytokine-mediated inflammation in acute lung injury[J]. Cytokine Growth Factor Rev, 2003, 14(6): 523-535.
[22] Yang G, Hamacher J, Gorshkov B, et al. The dual role of TNF in pulmonary edema[J]. J Cardiovasc Dis Res, 2010, 1(1): 29-36.
[23] Bhargava M, Wendt CH. Biomarkers in acute lung injury[J]. Transl Res, 2012, 159(4): 205-217.
[24] Quesnel C, Marchand-Adam S, Fabre A, et al. Regulation of hepatocyte growth factor secretion by fibroblasts in patients with acute lung injury[J]. Am J Physiol Lung Cell Mol Physiol, 2008, 294(2): L334-L343.
[25] Lin WC, Lin CF, Chen CL, et al. Prediction of outcome in patients with acute respiratory distress syndrome by bronchoalveolar lavage inflammatory mediators[J]. Exp Biol Med (Maywood), 2010, 235(1): 57-65.
[26] Parsons PE, Eisner MD, Thompson BT, et al. Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury[J]. Crit Care Med, 2005, 33(1): 1-6, 230-232.
[27] Lindsay CD. Novel therapeutic strategies for acute lung injury induced by lung damaging agents: the potential role of growth factors as treatment options[J]. Hum Exp Toxicol, 2011, 30(7): 701-724.
[28] Li X, Li S, Zhang M, et al. Protective effects of a bacterially expressed NIF-KGF fusion protein against bleomycin-induced acute lung injury in mice[J]. Acta Biochim Biophys Sin (Shanghai), 2010, 42(8): 548-557.
[29] 侯伟, 刘海燕, 李丹, 等. 新生大鼠高氧肺损伤血管内皮生长因子蛋白及其mRNA表达变化研究[J]. 中国当代儿科杂志, 2008, 10(2): 207-210.
[30] Yee M, White RJ, Awad HA, et al. Neonatal hyperoxia causes pulmonary vascular disease and shortens life span in aging mice[J]. Am J Pathol, 2011, 178(6): 2601-2610.
[31] Wada T, Jesmin S, Gando S, et al. The role of angiogenic factors and their soluble receptors in acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) associated with critical illness[J]. J Inflamm (Lond), 2013, 10(1): 6.
[32] Gonzalez-Lopez A, Albaiceta GM. Repair after acute lung injury: molecular mechanisms and therapeutic opportunities[J]. Crit Care, 2012, 16(2): 209.
[33] Barnett N, Ware LB. Biomarkers in acute lung injury-marking forward progress[J]. Crit Care Clin, 2011, 27(3): 661-683.
[34] Sapru A, Curley MA, Brady S, et al. Elevated PAI-1 is associated with poor clinical outcomes in pediatric patients with acute lung injury[J]. Intensive Care Med, 2010, 36(1): 157-163.
[35] Ware LB, Koyama T, Billheimer DD, et al. Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury[J]. Chest, 2010, 137(2): 288-296.